| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() DIABETES UK: Pravastatin Appears To Restore Endothelial Function In Type 1 Diabetes By David Jack, M.D. Special to DG News
GLASGOW, SCOTLAND -- April 5, 2001 -- Patients suffering from type 1 diabetes are at risk of developing atherosclerosis prematurely. The endothelial dysfunction is due to reduced bioavailability of endothelium-derived nitric oxide (NO) and this is a key factor in the pathogenesis of premature atherosclerosis.
Young adults with this form of diabetes exhibit impairment of flow-mediated dilatation and available evidence suggests that HMG-Co A reductase inhibitors (statins) can have beneficial effects on endothelial function.
A study presented at the Diabetes UK Annual Professional Meeting by Dr. K. Moore and colleagues of the Department of Surgery and Endocrinology, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland, showed the effects of a one-month treatment with pravastatin on flow-mediated-dilatation in eight young men (age 18-31) with type 1 diabetes (HbA1c 7.2 +/- 1.4 percent). Baseline data on eight age-matched controls was also obtained and flow-mediated dilation of the brachial artery was measured by high resolution ultrasonography. The increase in blood pressure was obtained by inflating a cuff on the distal forearm to a pressure of 240 mmHg for 4.5 minutes.
The mean flow-mediated dilatation in the diabetics rose from 4.5 percent pre-treatment to 8.44 percent post-treatment which is a highly significant increase ; the mean value in the control subjects was 7.98 percent.
This pilot study shows that a one-month treatment with pravastatin is able to reverse abnormal flow-mediated dilatation in young type 1 diabetics.
|